AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05736380 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cerebellar rTMS
Description: Sham cerebellar rTMS
Study NCT05479877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India
Description: Collagen based pulpotomy will be applied (sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India)according to the manufacturer's instructions and gently placed over the pulp stumps to a thickness of 2 mm
Study NCT05479877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biodentine (Septodont, Saint-Maur-des-Fossés, France)
Description: Biodentine (Septodont, Saint-Maur-des-Fossés, France) will be applied according to the manufacturer's instructions and placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet.
Study NCT05127954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Oral Tablet
Study NCT06474247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Postbiotic
Description: Postbiotic at 1g/day as an adjunct treatment against vaginal candidiasis in women for 4-weeks
Study NCT06474247 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo at 1g/day as an adjunct treatment against vaginal candidiasis in women for 4-weeks
Study NCT05397925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADSProgram - Self management for substance dependence program
Description: GENERAL STRUCTURE OF THE MODEL - 8 sessions: One initial - assessment; 1 to 6 Intermediates - empowerment (Flexible number of intermediate sessions according to the person's need and accessibility, interlude 1 week minimum, up to a maximum of 3 weeks); 1 Final - autonomy; Duration of sessions: 20-60 min; Context: Outpatient specialized addictions unit. Private room needed; Preferred approach: Individual, face-to-face or virtual consultation. Complementary approach: In groups of up to 4 people, when peer support or sharing feelings are needed: Clinical focus 1 - Concerning the problematic use of substances, 2 - Related to health knowledge in general, 3 - Related to health-seeking behavior and adherence, 4 - Related to self-knowledge and well-being, 5 - Related to social role and personal dignity, 6 - Related to the family process.
Study NCT05397925 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual - Regular nursing consultation on a medication-based program
Description: Regular individual assessment on: substance used (kind of substance, consumption way, frequency), way of living, social relationship, health status nursing diagnoses. To support on this, therapeutic interventions, medication delivery and management support.
Study NCT05023642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance training
Description: Interventions will include a three-phase strengthening training protocol.~1. Adaptation phase: three sessions, emphasis on learning the technique, body self-awareness, and movement coordination;~2. Basic phase: 12 sessions, to increase muscle strength; and~3. Specific phase: 21 sessions, to intensify the process of strength gain and muscular hypertrophy.~Participants will perform the following exercises during the strength-training protocol intervention: pec deck/seated lever fly, adductor, pulldown, abductor strengthening, alternating dumbbell curl, leg press at a 45-angle, triceps pulley, lateral raise, knee flexion and extension, ankle joint flexion and extension in the leg press, and crunches. If the participant has difficulty performing a specific exercise, an equivalent activity will replace it. From the eighth week onwards, participants will perform additional exercises focused on strengthening the gastrocnemius and soleus.
Study NCT05628064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1C70
Description: Investigational energy storage and return prosthetic foot with using novel elastic elements.
Study NCT05628064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pro-Flex XC
Description: Commercially available carbon-fiber energy storage and return foot used as comparative foot for transtibial amputee subjects.
Study NCT06436131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-phase Bilateral Exercise
Description: The exercise program of the experimental group consisted of exercises based on in-phase bilateral movements of the upper and lower limbs, which were adapted to different sport activities and to fitness functional exercises.~The participants of experimental group performed the specific type exercises three times per week, for 12 consecutive weeks.
Study NCT06436131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conservative exercises
Description: The participants of the active control group, underwent an exercise program based on conventional exercises, such as strengthening of the major muscle groups of the trunk, resistance exercises for the upper and lower limbs and body weight support treadmill exercise.
Study NCT05733832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transitional Liver Clinic (TLC)
Description: Participants in this intervention receive additional attention from their Hepatology providers in terms of an additional call/telemedicine visit and more specific/additional attention from their Hepatology APP (advanced practice provider) based on individual patient needs
Study NCT05657002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patient A with accurate problem list
Description: A problem list that contains a diagnosis code that is contraindicated with a type of medication (Y). Also, all other relevant diagnoses and medical history for the patient are up-to-date on the problem list, which was defined according to the problem list policy at our institution (i.e. all current active problems and relevant medical history should be documented on the problem list). Additionally, the problem list is included in eight out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. One note includes the problem list with the diagnosis relevant for the question asked.
Study NCT05657002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patient B with inaccurate problem list
Description: A problem list that does not contain the diagnosis code and corresponding details explaining medical history of this diagnosis caused by a type of medication (Y). Additionally, the problem list is included in three out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. The relevant diagnosis is not documented on the problem list and hence is not included in the imported problem list in the notes.~The expert panel provided and anonymized two real-world representative examples of hematology patient records that included inaccurate problem lists and that had many free-text notes. An 'inaccurate problem list' is defined as a problem list where diagnoses are missing resulting in missed trigger medication or order-alerts, where diagnoses are 'active' although they should be closed or removed and/or where the problem list contained duplicated diagnoses.
Study NCT05657002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patient A with inaccurate problem list
Description: A problem list that does not contain the diagnosis code that is contraindicated with the type of medication (Y). Additionally, the problem list is included in eight out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. The relevant diagnosis is not documented on the problem list and hence is not included in the imported problem list in the notes.~The expert panel provided and anonymized two real-world representative examples of hematology patient records that included inaccurate problem lists and that had many free-text notes. An 'inaccurate problem list' is defined as a problem list where diagnoses are missing resulting in missed trigger medication or order-alerts, where diagnoses are 'active' although they should be closed or removed and/or where the problem list contained duplicated diagnoses.
Study NCT05657002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patient B with accurate problem list
Description: A problem list that contains the diagnosis code and corresponding details explaining medical history of this diagnosis caused by a type of medication (Y). Also, all other relevant diagnoses and medical history for the patient are up-to-date on the problem list, which was defined according to the problem list policy at our institution (i.e. all current active problems and relevant medical history should be documented on the problem list). Additionally, the problem list is included in three out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. One note includes the problem list with the diagnosis and details relevant for the question asked.
Study NCT05007054 — intervention group
Intervention type: PROCEDURE
Intervention: PCI or CABG
Description: The PCI performed following current standard guidelines. All patients were pre-treated with aspirin and clopidogrel before catheterization. Thereafter, heparin (70-100 IU/kg) was administered before PCI, however, the use of glycoprotein IIb/IIIa inhibitors was at the physician's discretion. Dual-antiplatelet medication was administered to the patients after PCI for at least 12 months. For CABG, the left internal mammary artery was routinely used to graft to the left anterior descending artery and completed by venous grafts to other coronary branches with standard bypass techniques. The procedure was performed by surgeons experienced in on-pump or of-pump surgery at the operator's discretion.
Study NCT05375032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling combined with cognitive tasks
Description: A 30-minute session of Forced Cycling aerobic exercise performed with lower limbs and free active cycling performed with upper limbs combined with cognitive stimuli. An intelligent cycle ergometer (Motomed Viva 2 Parkinson) will be used, at a reserve heart rate of 55-70% (Borg scale 12-14) during the active part. The forced cycling program will consist of a 6-minute passive warm-up part (40-60 RPM), a 20-minute active part (90 RPM), and a 4-minute passive cool down (40 RPM). The cognitive task will be a PowerPoint presentation structured in a way that is consistent with the phases of the cycling program. The passive phases (6 minutes of warm-up and 4 minutes of passive cycling back to cool down), images of the nearby environment will be played. For the active phase (20 minutes of assisted active cycling) the PowerPoint presentation will be structured with tasks related to: orientation, memory, calculation, language, similarities.
Study NCT05375032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycling
Description: A 30-minute session of Forced Cycling aerobic exercise performed with lower limbs and free active cycling performed with upper limbs combined with cognitive stimuli. An intelligent cycle ergometer (Motomed Viva 2 Parkinson) will be used, at a reserve heart rate of 55-70% (Borg scale 12-14) during the active part. The forced cycling program will consist of a 6-minute passive warm-up part (40-60 RPM), a 20-minute active part (90 RPM), and a 4-minute passive cool down (40 RPM).
Study NCT05252650 — intervention group
Intervention type: BEHAVIORAL
Intervention: pain
Description: postoperative pain
Study NCT05130853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills and Neurocognitive Individualized Training (SoCIAL)
Description: SoCIAL is composed of two modules:~1. Social Cognition Training The Emotions recognition training will train the subject's ability in discriminating between different emotional states through photos and videos. The Theory of Mind (ToM) training will help subjects discriminate between emotional expressions in social contexts and understand other people's mental state with videos that display actors expressing several emotional states. More details in Palumbo et al., 2017.~2. Narrative Enhancement Training The narrative enhancement training consists in story-telling exercises focused on improving the subject's capacity to comprehend his/her emotional experience.
Study NCT05130853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatmment-as-usual
Description: Subjects that will be randomized in this group will receive their treatment as usual for the whole length of the study. TAU includes all the psychiatric therapies (pharmacological, psychological, occupational etc) that subjects may have begun before study's enrollment.
Study NCT05130853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatmment-as-usual
Description: Subjects that will be randomized in this group will receive their treatment as usual for the whole length of the study. TAU includes all the psychiatric therapies (pharmacological, psychological, occupational etc) that subjects may have begun before study's enrollment.
Study NCT06147284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive interventions
Description: Parallel randomized controlled trial
Study NCT06254768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: its a device used to measure glucose from interstitial fluids and provides feedback regarding the same every 5 minutes.
Study NCT05050994 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Children with symptomatic secondary splenomegaly will receive partial microwave ablation of spleen (up to 40-50% of total volume)
Study NCT05179226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Derisomaltose
Description: All subjects will be treated with Ferric derisomaltose 20 mg/kg at baseline visit except for 12 subjects included in the PK-group, who will be treated with 10 mg/kg
Study NCT06140589 — intervention group
Intervention type: DRUG
Intervention: Cadonilimab
Description: The intravenous dose of Cadonilimab was 10mg/kg, and every 3 weeks was a course of treatment; Or 6mg/kg, every 2 weeks for a course of treatment
Study NCT05674656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Rilpivirine FDC
Description: Dolutegravir/Rilpivirine will be administered.
Study NCT05376150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN1101 10 mg
Description: XEN1101 oral capsule
Study NCT05376150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN1101 20 mg
Description: XEN1101 oral capsule
Study NCT05376150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study NCT05459181 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HeartCare
Description: Using HeartCare platform as a tool to successfully augment immunosuppressant agents through regular surveillance allowing minimization of doses and number of agents.
Study NCT05766592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LGBTQ-affirmative CBT
Description: 16-session LGBTQ-affirmative psychotherapy using cognitive behavioral techniques
Study NCT05766592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABFT-SGM
Description: 16-session attachment-based family therapy for sexual and gender minority young adults and their nonaccepting parents
Study NCT04029883 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Message
Description: A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time.103 To keep the importance of routinizing pill-taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform.
Study NCT04029883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Economic Incentive
Description: In this group, participants will be eligible for a prize drawing if they take their medication within +/- 1 hour of the time they carry out their existing routine behavior on at least 80% of days between clinic visits.
Study NCT04029883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message
Description: A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time.103 To keep the importance of routinizing pill-taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform.
Study NCT05506657 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: State Counselor-Coordinated Services
Description: A counselor affiliated with the New Jersey State Division of Vocational Rehabilitation Services coordinates services that consider the participant's condition, needs and goals. Services participants may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers.
Study NCT06064279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Tol like receptor 3 agonist
Study NCT06064279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: pooled IVIG
Study NCT06378008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSPS toothpaste
Description: Toothpaste containing 5.0% weight/weight (w/w) CSPS.
Study NCT06378008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular fluoride toothpaste (Crest Cavity Protection)
Description: Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
Study NCT06553937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan and Tadalafil
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
Study NCT06553937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan and Tadalafil
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
Study NCT06553937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrOpsynvi® Film-Coated Tablets
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
Study NCT06553937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrOpsynvi® Film-Coated Tablets
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
Study NCT04837716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT04837716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT04837716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Given PO
Study NCT04837716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study NCT05411029 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 24 hour blood pressure (BP) monitoring
Description: 24-hour ambulatory BP measuring device and blood pressures will be measured every 20 minutes to half hour
Study NCT05411029 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: Measurements will include electroencephalogram, electromyogram, electrooculogram, electrocardiogram, breathing patterns of chest and abdomen, nasal and oral airflow and oxygen saturation. Sleep stages and apneas will be scored in accordance with validated American Academy of Sleep Medicine standards.
Study NCT05893888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRV211 (Intraoperative Cisplatin System)
Description: PRV211 system is comprised of two parts, a liquid permeation enhancer (PE) and cisplatin patch. The permeation is brushed onto the resected tumor bed and after 5 minutes the patch can be applied directly over the same area. Apply up to 2 layers of the PRV211 system to the tumor bed post-resection. The duration of the PRV211 treatment takes approximately 10-20 minutes and then the surgeon can continue as planned with the rest of the standard of care procedure. The proposed starting dose is 0.5 mg/cm2 of cisplatin on the tumor bed. This approach can be safe and effective in preventing locoregional recurrence after surgery and eliminating high-risk factors for local recurrence, such as dysplasia at the margins.
Study NCT05893888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRV111 (Cisplatin Transmucosal System)
Description: PRV111 (Cisplatin Transmucosal System) is a thin, 2-layer, matrix-type, transmucosal patch consisting of a chitosan matrix layer embedded with cisplatin loaded chitosan particles (CLPs) and a non-woven fabric adhesive unidirectional backing, which is applied to the matrix layer during manufacturing. The patch is self-adhesive. In addition to the PRV111 patch, a separately packaged Permeation Enhancer (PE) Powder for Reconstitution used in conjunction with PRV111. The reconstituted PE Solution is intended to improve the absorption of the cisplatin active ingredient and will be applied prior to patch application.
Study NCT05494190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m2 i.v. day 1
Study NCT05494190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60 mg/m2 i.v. day 1-3
Study NCT05494190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 750 mg/m2 po bid day 1-14
Study NCT05494190 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy
Description: Radiotherapy: using intensity-modulated radiation therapy (IMRT)~Gross tumor volume (GTV) for primary tumor: 66-70 Gy in total, 2.0\~2.2 Gy per day, 5 days per week~Clinical target volume (CTV) for lesions closely related to the primary lesion and metastatic lymph nodes: 65\~70 Gy in total, 1.7\~2.0 Gy per day, 5 days per week~Prophylactic irradiation for sites of suspected subclinical spread: 50\~60 Gy in total, 1.7\~2.0 Gy per day, 5 days per week~Concurrent chemotherapy: cisplatin 80 mg/m2 on days 1-3 every 3 weeks.